UK - LondonTechnology Fund backs vaccines for viruses technology

London Technology Fund (LTF) has completed an investment in Immune Targeting Systems (ITS) Ltd, a company which is developing vaccines for mutating viruses. LTF is participating in a ТЃ3.5m series-A funding round for ITS alongside Novartis Venture Fund (Switzerland), HealthCap (Sweden) and Truffle Capital (France). The London Development Agency will also be contributing an Exceptional Development Project award of ТЃ500,000 under the Grant for Research and Development scheme. As a result of the investment the company has been able to recruit its core team of development scientists and will move into dedicated facilities at the London BioScience Innovation Centre.